SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : 2023 Biotech Charity Contest -- Ignore unavailable to you. Want to Upgrade?


To: technetium who wrote (151)9/9/2023 8:38:34 PM
From: technetium  Respond to of 233
 
VRTX: The Billion Dollar Molecule by Barry Werth published 1994

en.wikipedia.org

Interesting read about struggles at a then early start-up.

Barry Werth wrote The Antidote, about Vertex twenty years later, but I haven’t read it.



To: technetium who wrote (151)9/10/2023 4:03:31 AM
From: Aloner  Respond to of 233
 
Cidara Therapeutics, Inc. (Nasdaq: CDTX), has announced that Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has delivered to Cidara its Election to Proceed Notice for CD388 (JNJ-0953) which is being developed for the universal prevention of influenza A and B. Responsibility for future development, manufacturing and commercialization activities of CD388 will be assumed by Janssen, which intends to transfer its rights and obligations under the agreement to another entity.

“The Election to Proceed notice represents an important accomplishment for CD388, the most advanced Cloudbreak ® DFC program,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. “The clinical and nonclinical data for CD388 support the potential for a single dose to provide universal protection from seasonal and pandemic influenza strains A and B. This milestone payment, in addition to potential future milestone payments, if achieved, will provide Cidara with additional non-dilutive capital that will be applied to advance our other Cloudbreak ® DFC programs.”

As part of its exclusive worldwide collaboration with Janssen, Cidara is studying CD388 in Phase 1 (NCT05285137 and NCT05619536) and 2a (NCT05523089) clinical trials evaluating safety and pharmacokinetics as well as efficacy as pre-exposure prophylaxis against an influenza virus in healthy volunteers during a human challenge study. Earlier this year, Cidara announced promising interim efficacy and safety data from the Phase 2a study. The interim analysis demonstrated that a single dose of CD388 decreased viral replication in the upper respiratory tract and lowered influenza incidence rate compared to placebo. As of the interim analysis, treatment with CD388 was generally well-tolerated, with no treatment emergent adverse events leading to study discontinuation or serious adverse events reported. Cidara continues to work in collaboration with Janssen to complete the Phase 1 and Phase 2a trials and will be reimbursed for all ongoing development activities by Janssen as provided in the Janssen Collaboration Agreement. The complete CD388 Phase 2a data package is currently anticipated to be delivered to Janssen later this year.

Cidara will receive a $7 million milestone payment from Janssen for the election to proceed for CD388 and other influenza DFCs. Under the collaboration agreement, Cidara is eligible to potentially receive an additional $685 million in development, regulatory and commercial milestones, plus tiered royalties on worldwide sales.



To: technetium who wrote (151)9/16/2023 10:48:33 AM
From: technetium2 Recommendations

Recommended By
BulbaMan
Lance Bredvold

  Read Replies (1) | Respond to of 233
 
After last week’s dismal contest report, we should be able to expect something better. And our expectations were answered! Albeit begrudgingly.

As far as the broader behavior the NASDAQ composite was down (-0.4%), and both biotech indices were down more (S&P Biotech composite off -1.9%). Looked at individually there was no particular news items to distinguish the winners, or the losers, for the week. NAUT had the best return (+37% of original price). Interestingly, almost all of that gain occurred during a burst of trading in the last 15 minutes of Friday, moving from $3.53 at 3:48 pm (EDT) to $3.94 at 4:00. So someone saw something they liked. This pushed NAUT into 4th place in the YTD standings, and otherwise the next four performers for the week were not part of the top 5 YTD performers. Not the case for this week’s losers. INZY, our best YTD performer turned in the worst week, -50% of its price at the start of the week. CRVS and MGTA were also significant losers, dropping from the YTD top five all together, bringing in ISEE in fifth (+87%). I note in passing that JSPR, in its fourth straight appearance in the weekly loser list, lost another -21%.

The average contest portfolio dropped another -$1.8k, though it outperformed the S&P composite.

Three portfolios were in the black for the week (that’s what checks the “expecting better” box). The winner for the week, STEVE LOKNESS (+$2.7k) owed his performance to a position in NAUT, that yielded more than his loss from holding MGTA, which left his YTD standing (4th place at +$17k) unchanged. The only change in the YTD top seven was by dint of not losing that much this week (-$770) RKRW moved into third YTD passing ERIKOTTO. Our first place position is still held by ALONER, but again holding CRVS and MGTA meant that he posted a net loss of -$5k for the week.

Taking everything together, we currently have only four portfolios in the black for the contest, but they are all separated by less than $10k, ALONER being only $7.8k ahead of RKRW. So the contest is certainly a real … contest, and with more than 3 months to go we might see a lot of action in the standings.
Report Time Ranges











From

To

















Recent

9/8/23

9/15/2023

















YTD

12/31/2022









Index Portfolios’ Performance









Symbol

Recent P/L

Recent %

YTD P/L

















^IXIC

-$508.19

-0.4%

$30,973.68

















^NBI

-$591.65

-0.6%

-$3,691.15

















^SPSIBI

-$1,836.19

-1.9%

-$7,077.95









Share Performance

Recent Performance

YTD Performance



Top Five



Bottom Five



Top Five



Bottom 5

Symbol

P/L / Initial Price

Symbol

P/L / Initial Price

Symbol

YTD P/L / Initial Price

Symbol

YTD P/L/ Initial Price

NAUT

36.7%

INZY

-49.5%

INZY

309.5%

APTA.L

-97.5%

CABA

21.1%

HUMA

-26.3%

PRVB

136.5%

AVTX

-97.4%

BLCM

12.5%

JSPR

-20.7%

MOR

124.6%

PTEIQ

-87.2%

CDTX

10.1%

CRVS

-20.0%

NAUT

118.9%

TCON

-83.0%

LRMR

9.9%

MGTA

-14.9%

ISEE

86.8%

ALT

-82.2%

Average and Median Portfolio Performance



Recent P/L







YTD P/L







Avg.

Median







Avg

Median







-$2,298.80

-$1,785.89

A.J. MULLEN



-$12,174.50

-$18,239.35

TECHNETIUM

Top Seven Portfolio Performances

Top Recent Performers

Top YTD Performers

Contestant (Prev. Rank)

Recent P/L

P/L vs. ^SPSIBI

YTD P/L (Rank)

Contestant (Prev. Rank)

YTD P/L

vs. Top Portfolio

P/L vs. ^SPSIBI

Rec. P/L (Rank)

1 - STEVE LOKNESS (12)

$2,691.16

$4,527.35

$17,210.59 (4)

1 - ALONER (1)

$27,134.05

——

$34,212.00

-$5,422.15 (13)

2 - DEW DILIGENCE (14)

$944.62

$2,780.81

-$26,273.57 (12)

2 - RKRW (3)

$19,648.69

$7,485.36

$26,726.64

-$767.85 (4)

3 - BMAZ001 (4)

$408.85

$2,245.03

-$51,467.15 (15)

3 - ERIKOTTO (2)

$18,844.79

$8,289.27

$25,922.74

-$2,495.09 (11)

4 - RKRW (9)

-$767.85

$1,068.33

$19,648.69 (2)

4 - STEVE LOKNESS (4)

$17,210.59

$9,923.46

$24,288.54

$2,691.16 (1)

5 - RAJU_BIJLEE (8)

-$839.23

$996.95

-$42,960.50 (14)

5 - BLADERUNNER (5)

-$1,663.01

$28,797.06

$5,414.94

-$8,582.16 (15)

6 - TOMATO (2)

-$1,334.61

$501.57

-$14,041.20 (7)

6 - A.J. MULLEN (6)

-$12,475.01

$39,609.06

-$5,397.06

-$1,785.89 (8)

7 - TECHNETIUM (6)

-$1,741.75

$94.44

-$18,239.35 (8)

7 - TOMATO (7)

-$14,041.20

$41,175.26

-$6,963.25

-$1,334.61 (6)

Top Portfolios’ Contents

Top Recent Performance Portfolio (STEVE LOKNESS)

Top YTD Performance Portfolio (ALONER)

Symbol (Rank)

Current Allocation

Value/Total | ROI

YTD Stock P/L

Recent Stock P/L

% Current Price Change for $1,000 P/L

Symbol (Rank)

Initial Allocation

Value/Total | ROI

YTD Stock P/L

Recent Stock P/L

% Current Price Change for $1,000 P/L

AKYA

15.0%

5.8% | -54.6%

-$8,197.49

$47.02

14.7%

AFMD

10%

4.4% | -55.8%

-$7,042.37

-$75.79

17.9%

CRBU

5.0%

4.0% | -6.7%

-$334.39

$79.62

21.4%

CDTX

10%

13.3% | 33.4%

$4,223.63

$1,206.39

5.9%

GRPH

10.0%

5.9% | -30.7%

-$3,072.29

$240.96

14.4%

CLSD

10%

7.5% | -24.8%

-$3,136.34

-$401.53

10.5%

MGTA

10.0%

15.1% | 77.1%

$7,711.39

-$1,486.08

5.6%

CRDF

10%

12.1% | 21.7%

$2,740.03

-$977.16

6.5%

MRUS

15.0%

20.2% | 57.5%

$8,629.61

$901.75

4.2%

CRIS

10%

8.3% | -16.9%

-$2,131.89

-$860.34

9.5%

NAUT

10.0%

18.7% | 118.9%

$11,888.89

$3,666.67

4.6%

CRVS

10%

17.5% | 76.0%

$9,602.54

-$2,391.89

4.5%

PACB

10.0%

10.9% | 27.4%

$2,738.39

$36.67

7.9%

KZIA

10%

14.5% | 45.5%

$5,749.12

-$767.84

5.4%

PSNL

15.0%

9.0% | -29.3%

-$4,393.94

-$795.45

9.4%

MGTA

10%

15.8% | 58.7%

$7,410.67

-$1,681.35

5.0%

QSI

10.0%

10.4% | 22.4%

$2,240.44

$0.00

8.2%

MRNA

10%

6.8% | -31.1%

-$3,933.18

$527.35

11.5%













PRVB

10%

0.0% | 136.5%

$13,651.84

$0.00

--